AR005229A1 - Un derivado de 2,3-dioxo-1,2,3,4-tetrahidro-quinoxaliil y una composicion farmaceutica que lo comprende. - Google Patents
Un derivado de 2,3-dioxo-1,2,3,4-tetrahidro-quinoxaliil y una composicion farmaceutica que lo comprende.Info
- Publication number
- AR005229A1 AR005229A1 ARP960104160A AR10416096A AR005229A1 AR 005229 A1 AR005229 A1 AR 005229A1 AR P960104160 A ARP960104160 A AR P960104160A AR 10416096 A AR10416096 A AR 10416096A AR 005229 A1 AR005229 A1 AR 005229A1
- Authority
- AR
- Argentina
- Prior art keywords
- aliphatic
- radical
- acid
- alk
- unsubstituted
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 8
- 150000003254 radicals Chemical class 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- -1 2,3-dioxo1,2,3,4-tetrahydro-quinoxalinyl Chemical class 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003008 phosphonic acid esters Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
- C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un derivado de 2,3-dioxo1,2,3,4-tetrahidro-quinoxalinil de fórmula (I), donde uno de los radicales R1 y R2 es un grupo R5 y el otro es un grupo defórmula: -CH(R6)-alq-R7(Ia),-alq-CH(R6)-R7(Ib),alq-N(R9)-X-R7(Ic),-alq-N(+)(R9) (R9)-X-R7A(-)(Id)-al q-O-X-R7(Ie) o -alq-S-X-R7 (If); R3,R4 y R5 son cada unode ellos independientemente de los demás hidrógeno, alquilo inferior, halógeno, trifluoro-metil, ciano o nitro; R6 es amino insustituido o alquilado inferiory/o alcanoilado inferior; R7 es hidrógeno, un radical alifático, cicloalifático o heterocicloalifático, ciano, acilo derivado de ácidocarbónico o de un semiéster o semiamida de ácido carbónico, de ácido sulfúrico o de un ácido sulfónico alifático o aromático o de un ácid o fosfórico ode unéster de ácido fosfónico, amino insustituido o alifático o aralifáticamente sustituido y/o sustituido por aciloalifático, aralifático o aromático, o unradical aromático o heteroaromático; R8 es hidrógeno, un radical alifático o aralifático,o acilo derivado de un ácido carboxílico alifático o aralifáticoo de un semiéster alifático o aralifático de ácido carbónico; o R7 y R9 junto con X y el átomo de nitrógeno que liga R6 y X, forman un mono- o di-azacicloalquilo, azox acicloalquilo,azatiacicloalquilo insustituido o sustituido u opcionalmente un radical oxidado tiacicloalquilo enlazado con unátomo de nitrógeno, o un radical arilo o heteroarilo insustituido o sustituido, opcionalmente parcialmente hidroge nado; R9 es un radicalalifático oaralifático; o R7,R8 y R9, junto con X y el átomo de nitrógeno que liga R8, R9 y X, forman un radical heteroarilo cuaternario insustituido o sustituidoenlazado a través del átomo de nitrógeno cuaternario, siendo A(- ) el anión de unácido protónico; alq es alquileno inferior; y X (salvo que, junto con R7 y
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH247995 | 1995-08-31 | ||
| CH273495 | 1995-09-27 | ||
| CH274795 | 1995-09-28 | ||
| CH121396 | 1996-05-10 | ||
| CH163096 | 1996-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005229A1 true AR005229A1 (es) | 1999-04-28 |
Family
ID=27508939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960104160A AR005229A1 (es) | 1995-08-31 | 1996-08-30 | Un derivado de 2,3-dioxo-1,2,3,4-tetrahidro-quinoxaliil y una composicion farmaceutica que lo comprende. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6080743A (es) |
| EP (1) | EP0853617B1 (es) |
| JP (1) | JP3159711B2 (es) |
| KR (1) | KR100462337B1 (es) |
| CN (1) | CN1137886C (es) |
| AR (1) | AR005229A1 (es) |
| AT (1) | ATE260902T1 (es) |
| AU (1) | AU705871B2 (es) |
| BR (1) | BRPI9603626B8 (es) |
| CA (1) | CA2227851C (es) |
| CZ (1) | CZ56298A3 (es) |
| DE (1) | DE69631774T2 (es) |
| DK (1) | DK0853617T3 (es) |
| ES (1) | ES2217324T3 (es) |
| HK (1) | HK1010196A1 (es) |
| HU (1) | HUP9801676A3 (es) |
| IL (1) | IL122987A (es) |
| MY (1) | MY132385A (es) |
| NO (1) | NO310236B1 (es) |
| NZ (1) | NZ316497A (es) |
| PL (1) | PL189637B1 (es) |
| PT (1) | PT853617E (es) |
| SI (1) | SI0853617T1 (es) |
| SK (1) | SK25298A3 (es) |
| TR (1) | TR199800349T2 (es) |
| WO (1) | WO1997008155A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997046539A1 (en) * | 1996-06-05 | 1997-12-11 | Warner-Lambert Company | Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| PT934326E (pt) * | 1996-10-24 | 2006-08-31 | Novartis Ag | Acidos aminoalcanofosfonicos substituidos |
| ZA9710553B (en) * | 1996-11-25 | 1998-06-10 | Warner Lambert Co | Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists. |
| GB9702194D0 (en) | 1997-02-04 | 1997-03-26 | Lilly Co Eli | Sulphonide derivatives |
| US6172065B1 (en) * | 1997-03-04 | 2001-01-09 | Warner-Lambert Company | Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| US6340758B1 (en) | 1997-05-16 | 2002-01-22 | Warner-Lambert Company | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents |
| US6096744A (en) * | 1998-05-04 | 2000-08-01 | Warner-Lambert Company | Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| US6677332B1 (en) | 1999-05-25 | 2004-01-13 | Sepracor, Inc. | Heterocyclic analgesic compounds and methods of use thereof |
| US6635661B2 (en) | 2000-05-25 | 2003-10-21 | Sepracor Inc. | Heterocyclic analgesic compounds and methods of use thereof |
| US7361666B2 (en) | 1999-05-25 | 2008-04-22 | Sepracor, Inc. | Heterocyclic analgesic compounds and methods of use thereof |
| WO2001092226A1 (en) * | 2000-05-25 | 2001-12-06 | Sepracor, Inc. | Heterocyclic analgesic compounds and method of use thereof |
| WO2002072542A2 (en) * | 2001-03-08 | 2002-09-19 | Emory University | Ph-dependent nmda receptor antagonists |
| TW200403066A (en) * | 2002-04-30 | 2004-03-01 | Novartis Ag | New uses of substituted aminoalkanephosphonic acids |
| US7524837B2 (en) * | 2003-05-12 | 2009-04-28 | Janssen Pharmaceutica N.V. | Benzotriazapinone salts and methods for using same |
| GB0310868D0 (en) * | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
| JP2007507514A (ja) * | 2003-09-30 | 2007-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キノキサリン化合物 |
| US20060020029A1 (en) * | 2004-07-02 | 2006-01-26 | Shimasaki Craig D | Pharmaceutical compositions from ethnobotanicals |
| UA95788C2 (en) * | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
| KR20100045983A (ko) * | 2007-06-29 | 2010-05-04 | 에모리 유니버시티 | 신경보호를 위한 ｎｍｄａ 수용체 길항물질 |
| CN102906085A (zh) * | 2010-05-20 | 2013-01-30 | 诺瓦提斯公司 | 2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基-磺酰胺衍生物 |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| JO3225B1 (ar) * | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
| CN103435561B (zh) * | 2013-08-19 | 2016-08-10 | 上海交通大学 | 一种新型d-氨基酸氧化酶抑制剂及其制备和应用 |
| AU2018211529A1 (en) | 2017-01-27 | 2019-08-29 | Genfit | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxa zin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases |
| KR102609676B1 (ko) | 2017-06-12 | 2023-12-05 | 글리테크 엘엘씨. | Nmda 길항제 및 d2/5ht2a 또는 선택적 5ht2a 길항제를 이용한 우울증의 치료 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4156734A (en) * | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
| CA2002864C (en) * | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| JPH04506967A (ja) * | 1989-07-27 | 1992-12-03 | ジー．ディー．サール アンド カンパニー | 高血圧症治療用腎選択性生成物 |
| US5631373A (en) * | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
| GB9418443D0 (en) * | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
| GB9419318D0 (en) * | 1994-09-24 | 1994-11-09 | Pfizer Ltd | Therapeutic agents |
-
1996
- 1996-08-12 MY MYPI96003300A patent/MY132385A/en unknown
- 1996-08-19 TR TR1998/00349T patent/TR199800349T2/xx unknown
- 1996-08-19 JP JP50980197A patent/JP3159711B2/ja not_active Expired - Fee Related
- 1996-08-19 DE DE69631774T patent/DE69631774T2/de not_active Expired - Lifetime
- 1996-08-19 AU AU68742/96A patent/AU705871B2/en not_active Ceased
- 1996-08-19 CZ CZ98562A patent/CZ56298A3/cs unknown
- 1996-08-19 SK SK252-98A patent/SK25298A3/sk unknown
- 1996-08-19 SI SI9630678T patent/SI0853617T1/xx unknown
- 1996-08-19 NZ NZ316497A patent/NZ316497A/xx unknown
- 1996-08-19 US US09/029,525 patent/US6080743A/en not_active Expired - Lifetime
- 1996-08-19 CA CA002227851A patent/CA2227851C/en not_active Expired - Fee Related
- 1996-08-19 KR KR10-1998-0701511A patent/KR100462337B1/ko not_active IP Right Cessation
- 1996-08-19 IL IL12298796A patent/IL122987A/en not_active IP Right Cessation
- 1996-08-19 DK DK96929275T patent/DK0853617T3/da active
- 1996-08-19 EP EP96929275A patent/EP0853617B1/en not_active Expired - Lifetime
- 1996-08-19 CN CNB961965819A patent/CN1137886C/zh not_active Expired - Fee Related
- 1996-08-19 PT PT96929275T patent/PT853617E/pt unknown
- 1996-08-19 AT AT96929275T patent/ATE260902T1/de active
- 1996-08-19 HU HU9801676A patent/HUP9801676A3/hu unknown
- 1996-08-19 WO PCT/EP1996/003644 patent/WO1997008155A1/en not_active Application Discontinuation
- 1996-08-19 PL PL96324992A patent/PL189637B1/pl not_active IP Right Cessation
- 1996-08-19 ES ES96929275T patent/ES2217324T3/es not_active Expired - Lifetime
- 1996-08-30 BR BRPI9603626A patent/BRPI9603626B8/pt not_active IP Right Cessation
- 1996-08-30 AR ARP960104160A patent/AR005229A1/es active IP Right Grant
-
1998
- 1998-02-26 NO NO19980814A patent/NO310236B1/no unknown
- 1998-10-16 HK HK98111287A patent/HK1010196A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR005229A1 (es) | Un derivado de 2,3-dioxo-1,2,3,4-tetrahidro-quinoxaliil y una composicion farmaceutica que lo comprende. | |
| ES2072779T3 (es) | Derivados aminoacidos anfoteros. | |
| AR016001A1 (es) | Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente | |
| ES2053508T3 (es) | Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos. | |
| ES2055056T3 (es) | Derivados de pirimidopirimidina. | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| ES2094309T3 (es) | Esteres de acidos grasos de acido isetionico alcoxilado y composiciones detergentes que comprenden los mismos. | |
| AR011101A1 (es) | Compuesto derivado de acidos arilsulfonilaminohidroxiamicos y composicion farmaceutica que lo contiene | |
| AR018634A1 (es) | Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos. | |
| CO4950558A1 (es) | Moduladores de receptores de aminoacidos excitadores | |
| MX9305379A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene. | |
| UY25682A1 (es) | Procedimiento para preparar derivados de quinolin-2-ona alquinilsustituidos útiles como agentes anticancerosos entre otras acciones terapéuticas | |
| ES2136930T3 (es) | Procedimiento para la oxidacion de alcoholes primarios o secundarios. | |
| AR247732A1 (es) | Procedimiento para obtener amidas de acido piridin-2, 4- y -2, 5-dicarboxilico | |
| MX162950B (es) | Procedimiento para preparar derivados de acidos piridoncarboxilicos | |
| ES2118203T3 (es) | Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| DK71780A (da) | Fremgangsmaade til fremstilling af difenylhydantoinderivater | |
| AR246509A1 (es) | Una cetimina, su preparacion y un agente de entrecruzamiento que la contiene. | |
| PA8458301A1 (es) | 2-aminopiridinas con sustituyentes alcoxi ramificados | |
| CO4980887A1 (es) | Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico | |
| CO5070654A1 (es) | Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden | |
| ES2045219T3 (es) | Procedimiento para la preparacion de derivados del acido fenoxicarboxilico. | |
| MY118638A (en) | 1,5-benzodiazepine derivatives | |
| ES2055115T3 (es) | Derivados de fenil-amidina y fenil-guanidina sustituidos en posicion orto y agentes antidiabeticos y hipoglicemicos que los contienen. | |
| ES543786A0 (es) | Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo dietilaminoalcoxi sustituido y sus sales deadicion acidas y amonicas cuaternarias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |